Hepatitis B virus inhibits the expression of CD82 through hypermethylation of its promoter in hepatoma cells

Yu,Guozheng; Bing,Yuntao; Li,Wei; Xia,Lin; Liu,Zhisu

doi:10.3892/mmr.2014.2495

Hepatitis B virus inhibits the expression of CD82 through hypermethylation of its promoter in hepatoma cells

Authors:
- Guozheng Yu
- Yuntao Bing
- Wei Li
- Lin Xia
- Zhisu Liu
View Affiliations

Affiliations: Department of General Surgery, Research Center of Digestive Diseases, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Head and Neck Surgery, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China, Department of Internal Medicine Oncology, Huangshi Central Hospital, Huangshi, Hubei 435005, P.R. China
Published online on: August 14, 2014 https://doi.org/10.3892/mmr.2014.2495
Pages: 2580-2586

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor suppressor gene CD82, also known as KAI1, may act as a general suppressor of metastasis in numerous types of cancer. It is hypothesized that downregulation of CD82 gene expression may be an important factor in the induction of hepatocellular carcinoma (HCC), however the mechanism for this requires further study. In the present study, the relative mRNA and protein expression levels of the CD82 gene were determined in HCC and adjacent non‑tumor tissues. The association between the CD82 gene and the hepatitis B virus (HBV) was also investigated, by quantitative polymerase chain reaction, western blotting, luciferase reporter assays and mass spectrometry with matrix‑assisted laser desorption/ionization time‑of‑flight mass array. CD82 expression was shown to be suppressed in response to HCC promoter methylation. Relative CD82 mRNA and protein expression levels were downregulated in HCC tissues (P<0.05). HBx protein inhibited CD82 promoter activity and subsequently the mRNA and protein expression levels. Furthermore, it was demonstrated that HBV could inhibit the expression of CD82 at the transcriptional level, and repress the activity of the CD82 promoter through hypermethylation. In addition, the methyl enzyme inhibitor 5‑aza‑CdR could induce the CD82 promoter activity and the relative expression level of CD82 mRNA, as observed by an increase in luciferase activity driven by the CD82 promoter. The observations of the present study suggest that hypermethylation of the CD82 promoter may be an event leading to the development of HCC. Low expression of CD82 is likely to be involved in tumor progression. HBV may inhibit the expression of CD82 through hypermethylation of the promoter in hepatoma cells.

View Figures

View References

1	Benhenda S, Cougot D, Buendia MA and Neuveut C: Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv Cancer Res. 103:75–109. 2009.PubMed/NCBI
2	Feitelson MA and Lee J: Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 252:157–170. 2007. View Article : Google Scholar : PubMed/NCBI
3	Chan DW and Ng IO: Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. J Pathol. 208:372–380. 2006. View Article : Google Scholar : PubMed/NCBI
4	Cheng AS, Wong N, Tse AM, Chan KY, Chan KK, Sung JJ and Chan HL: RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. Cancer Lett. 253:43–52. 2007. View Article : Google Scholar
5	Zhang X, Zhang H and Ye L: Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med. 147:58–66. 2006. View Article : Google Scholar : PubMed/NCBI
6	Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S, Kim CW and Kim KW: Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J. 18:382–384. 2004.PubMed/NCBI
7	Robinson WS: Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu Rev Med. 45:297–323. 1994. View Article : Google Scholar : PubMed/NCBI
8	Nephew KP and Huang TH: Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 190:125–133. 2003. View Article : Google Scholar : PubMed/NCBI
9	Li J, Lin S, Chen Q, Peng L, Zhai J, Liu Y and Yuan Z: Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol. 84:6387–6399. 2010. View Article : Google Scholar : PubMed/NCBI
10	Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI
11	Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC: CD82, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268:884–886. 1995. View Article : Google Scholar
12	Miranti CK: Controlling cell surface dynamics and signaling: how CD82/CD82 suppresses metastasis. Cell Signal. 21:196–211. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ai X, Zhang X, Wu Z, Ma X, Ju Z, Wang B and Shi T: Expression of CD82/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder. J Huazhong Univ Sci Technolog Med Sci. 27:79–82. 2007. View Article : Google Scholar : PubMed/NCBI
14	Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M and De Marzo AM: Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci. 12:4254–4266. 2007. View Article : Google Scholar : PubMed/NCBI
15	Dalmay T and Edwards DR: MicroRNAs and the hallmarks of cancer. Oncogene. 25:6170–6175. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
17	Zhu J: DNA methylation and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 13:265–73. 2006. View Article : Google Scholar : PubMed/NCBI
18	Yang B, Guo M, Herman JG and Clark DP: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 163:1101–1107. 2003. View Article : Google Scholar : PubMed/NCBI
19	Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ and Kang GH: Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 163:1371–1378. 2003. View Article : Google Scholar : PubMed/NCBI
20	Pogribny IP and Rusyn I: Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 342:223–230. 2014. View Article : Google Scholar : PubMed/NCBI
21	Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI
22	Li LH, He J, Hua D, Guo ZJ and Gao Q: Lentivirus-mediated inhibition of Med19 suppresses growth of breast cancer cells in vitro. Cancer Chemother Pharmacol. 68:207–215. 2011. View Article : Google Scholar : PubMed/NCBI
23	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI